Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lgh-447. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 known ✓ | Q9P1W9 | 20/20 | 1.00 |
| ▸ | PIM1 known ✓ | P11309 | 19/20 | 1.00 |
| ▸ | PIM3 known ✓ | Q86V86 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lgh-447 SCHEMBL3224824 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL1711495 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL3224835 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL29379725 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL1711499 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL3210796 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL3210815 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| Lgh-447 SCHEMBL3215332 | 1.00 | PIM2 (1.00) | PIM2PIM1PIM3GSK3BPRKCQ | |
| SCHEMBL16982480 | 0.94 | PIM1 (0.90) | PIM2PIM1PIM3GSK3BPRKCQ | |
| SCHEMBL12077297 | 0.93 | PIM2 (0.90) | PIM2PIM1PIM3GSK3BPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000951-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2021-01-07 | — | — | US | claimed |
| EP-3662903-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2020-06-10 | — | — | EP | claimed |
| US-20190290627-A1 | PIM KINASE INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2019-09-26 | — | — | US | claimed |
| US-20170368044-A1 | PIM KINASE INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-12-28 | — | — | US | claimed |
| EP-3200775-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-08-09 | — | — | EP | claimed |
| US-20160175293-A1 | PIM KINASE INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | claimed |
| EP-3030237-A1 | PIM KINASE INHIBITOR COMBINATIONS | Novartis AG (CH) | 2016-06-15 | — | — | EP | claimed |
| WO-2016054555-A2 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-04-07 | — | — | WO | claimed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | claimed |
| WO-2015019320-A1 | PIM KINASE INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2015-02-12 | — | — | WO | claimed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | claimed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | disclosed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| US-8592455-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2013-11-26 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | PIM2 2362/4885PIM1 2192/4885PIM3 1078/4885 |
| US-20190290627-A1 | PIM KINASE INHIBITOR COMBINATIONS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20170368044-A1 | PIM KINASE INHIBITOR COMBINATIONS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | PIM2 762/4885PIM1 481/4885PIM3 190/4885 |
| US-20210000951-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | PIM2 844/4885PIM1 782/4885PIM3 913/4885 |
| US-20160175293-A1 | PIM KINASE INHIBITOR COMBINATIONS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | CD47, CD2, CD58 | PIM2 1018/4885PIM1 979/4885PIM3 198/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PIM2 502/4885PIM1 204/4885PIM3 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.